gene therapy, Regeneron Pharmaceuticals and deafness

Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one-time treatment.
Gene therapy improves vision in children with genetic condition
The vision of one child with AIPL1-associated severe retinal dystrophy improved from light perception to naming his favourite cars from several metres away
Regeneron gene therapy helps deaf children hear in small study
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s treatment, new data show.
Regeneron’s Gene Therapy Restores Hearing in Patients with Rare Genetic Deafness
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.
Regeneron reports positive results for deafness therapy
Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment of profound genetic hearing loss in children due to certain variants of the OTOF gene.
What a $2 million per dose gene therapy reveals about drug pricing
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Gene Therapy: Revolutionizing Medicine By Tackling Diseases At Their Genetic Roots
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Rolling Out3d
Advanced gene therapy lights hope for vision loss patients
Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Making Gene Therapy Faster And Better With Fuse Vectors
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Gene therapy experiment gives children 'life-changing' sight boost
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
CompareNetworks publishes inaugural issue of Cell & Gene Therapy Review, delivering essential insights for a rapidly evolving industry
CompareNetworks is proud to announce the publication of the first issue of Cell & Gene Therapy Review, marking a significant ...